Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 880.66
SGMO's Cash to Debt is ranked higher than
56% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. SGMO: 880.66 )
Ranked among companies with meaningful Cash to Debt only.
SGMO' s Cash to Debt Range Over the Past 10 Years
Min: 1.71  Med: 10000.00 Max: No Debt
Current: 880.66
Equity to Asset 0.91
SGMO's Equity to Asset is ranked higher than
88% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SGMO: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
SGMO' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.88 Max: 0.99
Current: 0.91
0.39
0.99
Interest Coverage N/A
SGMO's Interest Coverage is ranked higher than
52% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SGMO: N/A )
Ranked among companies with meaningful Interest Coverage only.
SGMO' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: N/A
F-Score: 2
Z-Score: 11.54
M-Score: -3.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -191.12
SGMO's Operating margin (%) is ranked lower than
60% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. SGMO: -191.12 )
Ranked among companies with meaningful Operating margin (%) only.
SGMO' s Operating margin (%) Range Over the Past 10 Years
Min: -347.14  Med: -119.18 Max: -58.38
Current: -191.12
-347.14
-58.38
Net-margin (%) -172.98
SGMO's Net-margin (%) is ranked lower than
59% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. SGMO: -172.98 )
Ranked among companies with meaningful Net-margin (%) only.
SGMO' s Net-margin (%) Range Over the Past 10 Years
Min: -346.45  Med: -114.89 Max: -57.59
Current: -172.98
-346.45
-57.59
ROE (%) -26.39
SGMO's ROE (%) is ranked higher than
55% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. SGMO: -26.39 )
Ranked among companies with meaningful ROE (%) only.
SGMO' s ROE (%) Range Over the Past 10 Years
Min: -52.56  Med: -33.13 Max: -16.09
Current: -26.39
-52.56
-16.09
ROA (%) -23.26
SGMO's ROA (%) is ranked higher than
55% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. SGMO: -23.26 )
Ranked among companies with meaningful ROA (%) only.
SGMO' s ROA (%) Range Over the Past 10 Years
Min: -47.56  Med: -28.49 Max: -13.76
Current: -23.26
-47.56
-13.76
ROC (Joel Greenblatt) (%) -1864.91
SGMO's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SGMO: -1864.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGMO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3614.47  Med: -1833.88 Max: -1066.04
Current: -1864.91
-3614.47
-1066.04
Revenue Growth (3Y)(%) 11.30
SGMO's Revenue Growth (3Y)(%) is ranked higher than
64% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SGMO: 11.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGMO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.3  Med: -2.10 Max: 67.4
Current: 11.3
-37.3
67.4
EBITDA Growth (3Y)(%) 17.30
SGMO's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. SGMO: 17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGMO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.4  Med: 4.60 Max: 104.7
Current: 17.3
-24.4
104.7
EPS Growth (3Y)(%) 11.40
SGMO's EPS Growth (3Y)(%) is ranked higher than
70% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. SGMO: 11.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGMO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.9  Med: -1.50 Max: 184.4
Current: 11.4
-24.9
184.4
» SGMO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SGMO Guru Trades in Q2 2015

Joel Greenblatt 30,334 sh (New)
Jim Simons 107,697 sh (New)
Steven Cohen 320,300 sh (+63.34%)
First Eagle Investment 4,017 sh (unchged)
First Eagle Investment Sold Out
» More
Q3 2015

SGMO Guru Trades in Q3 2015

First Eagle Investment 200,000 sh (New)
Chuck Royce 212,100 sh (New)
Jim Simons 486,352 sh (+351.59%)
First Eagle Investment 6,517 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 28,300 sh (-91.16%)
» More
Q4 2015

SGMO Guru Trades in Q4 2015

Steven Cohen 600,300 sh (+2021.20%)
Chuck Royce 312,100 sh (+47.15%)
First Eagle Investment 3,259 sh (unchged)
First Eagle Investment 200,000 sh (unchged)
Jim Simons 209,400 sh (-56.94%)
» More
Q1 2016

SGMO Guru Trades in Q1 2016

Jim Simons 504,064 sh (+140.72%)
First Eagle Investment 379,727 sh (+89.86%)
Chuck Royce 456,100 sh (+46.14%)
Steven Cohen 348,200 sh (-42.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ARNA, NAS:AGEN, OTCPK:ZLDPF, NAS:ENTA, NAS:PGNX, NAS:MYOK, NAS:GERN, OTCPK:PTCHF, NAS:CYTK, NAS:ACRS, NAS:RVNC, NAS:OMER, NAS:MNKD, NAS:CTMX, NAS:AMRN, NAS:NDRM, NAS:BLCM, NAS:TLGT, NAS:VYGR, NAS:OMED » details
Traded in other countries:GBY.Germany, SGMO.Switzerland, 0R1D.UK,
Sangamo BioSciences Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development & commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.

Sangamo BioSciences Inc was incorporated in the State of Delaware on June 22, 1995. The Company is a clinical stage biopharmaceutical company engaged in the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. Its proprietary zinc finger DNA-binding proteins (ZFP) technology enables efficient and specific genome editing and gene regulation and it is developing ZFP Therapeutics; novel therapeutic products for the treatment of genetic disease. It has several proprietary clinical and preclinical programs in development and has strategically partnered certain programs with biopharmaceutical companies to obtain funding for its own programs and to expedite clinical and commercial development. The Company and its licensed partners are engaged in the research, development and commercialization of ZFPs, a naturally occurring class of proteins found in humans. It has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes (genome editing) and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off (gene regulation). As ZFPs act at the DNA level, it potentially has broad and fundamental applications in several areas, including human therapeutics, plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering. In the process of developing this platform the Company has accrued scientific, manufacturing and regulatory capabilities and know-how that is generally applicable in the broader field of gene therapy. The Company is engaged in the development of novel human therapeutics. Its ZFP Therapeutic, SB-728, a ZFN-modified autologous cell product for the treatment of HIV/AIDS, is the first therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase 2 study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase 1/2 study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It is also initiating Phase 1/2 studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B and MPS I, a lysosomal storage disorder (LSD). In addition, it has proprietary preclinical programs in hemophilia A and other LSDs and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy. The Company's competitors are - Protein pharmaceuticals under development at pharmaceutical and biotechnology companies such as Pfizer, Baxter, Bayer, Novo Nordisk, Genzyme, Shire, BioMarin, Biogen, Acceleron and numerous other pharmaceutical and biotechnology firms; Gene therapy companies developing gene-based products in clinical trials. Compet

Ratios

vs
industry
vs
history
P/B 2.42
SGMO's P/B is ranked higher than
66% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. SGMO: 2.42 )
Ranked among companies with meaningful P/B only.
SGMO' s P/B Range Over the Past 10 Years
Min: 1.47  Med: 4.35 Max: 11.13
Current: 2.42
1.47
11.13
P/S 14.30
SGMO's P/S is ranked lower than
52% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. SGMO: 14.30 )
Ranked among companies with meaningful P/S only.
SGMO' s P/S Range Over the Past 10 Years
Min: 4.72  Med: 20.61 Max: 97.2
Current: 14.3
4.72
97.2
EV-to-EBIT -4.29
SGMO's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. SGMO: -4.29 )
Ranked among companies with meaningful EV-to-EBIT only.
SGMO' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.3  Med: -9.20 Max: -0.9
Current: -4.29
-45.3
-0.9
EV-to-EBITDA -4.39
SGMO's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. SGMO: -4.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.3  Med: -9.40 Max: -0.9
Current: -4.39
-46.3
-0.9
Current Ratio 18.94
SGMO's Current Ratio is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SGMO: 18.94 )
Ranked among companies with meaningful Current Ratio only.
SGMO' s Current Ratio Range Over the Past 10 Years
Min: 5.06  Med: 12.08 Max: 55.31
Current: 18.94
5.06
55.31
Quick Ratio 18.94
SGMO's Quick Ratio is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. SGMO: 18.94 )
Ranked among companies with meaningful Quick Ratio only.
SGMO' s Quick Ratio Range Over the Past 10 Years
Min: 5.06  Med: 12.08 Max: 55.31
Current: 18.94
5.06
55.31
Days Sales Outstanding 31.24
SGMO's Days Sales Outstanding is ranked higher than
74% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. SGMO: 31.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.14  Med: 22.91 Max: 82.5
Current: 31.24
1.14
82.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.42
SGMO's Price/Net Cash is ranked higher than
78% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. SGMO: 2.42 )
Ranked among companies with meaningful Price/Net Cash only.
SGMO' s Price/Net Cash Range Over the Past 10 Years
Min: 0.96  Med: 4.10 Max: 17.78
Current: 2.42
0.96
17.78
Price/Net Current Asset Value 2.37
SGMO's Price/Net Current Asset Value is ranked higher than
77% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. SGMO: 2.37 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGMO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.93  Med: 3.96 Max: 17.45
Current: 2.37
0.93
17.45
Price/Tangible Book 2.31
SGMO's Price/Tangible Book is ranked higher than
71% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SGMO: 2.31 )
Ranked among companies with meaningful Price/Tangible Book only.
SGMO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.89  Med: 3.80 Max: 12.57
Current: 2.31
0.89
12.57
Price/Median PS Value 0.66
SGMO's Price/Median PS Value is ranked higher than
73% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SGMO: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
SGMO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.17 Max: 8.95
Current: 0.66
0.28
8.95
Earnings Yield (Greenblatt) (%) -23.25
SGMO's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. SGMO: -23.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGMO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -43.21  Med: 0.00 Max: 0
Current: -23.25
-43.21
0

More Statistics

Revenue (TTM) (Mil) $29.99
EPS (TTM) $ -0.73
Beta2.85
Short Percentage of Float14.25%
52-Week Range $4.63 - 9.91
Shares Outstanding (Mil)70.49

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 23 23 4
EPS ($) -0.79 -0.86 -1.16
EPS w/o NRI ($) -0.79 -0.86 -1.16
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SGMO

Headlines

Articles On GuruFocus.com
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 03 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Sangamo BioSciences Reveals New Gene Therapy Clinical Development Program For Hemophilia A Treatment Jul 26 2016
Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of... Jul 26 2016
11:46 am Sangamo BioSci announces the presentation of preclinical data that 'supports' the clinical... Jul 26 2016
Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of... Jul 26 2016
Coverage Initiated on Select Biotech Stocks Jul 18 2016
Sangamo BioSciences Announces Participation At Upcoming Scientific Conferences in July Jul 12 2016
Sangamo BioSciences Announces Participation At Upcoming Scientific Conferences in July Jul 12 2016
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 08 2016
Sangamo BioSciences Gets FDA Approval For IND For ZFN-Mediated Genome Editing Treatment Of MPS II Jun 20 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated... Jun 20 2016
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated... Jun 20 2016
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... Jun 15 2016
Premarket Research Report Covering the Biotech Industry Jun 15 2016
Sangamo BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : June... Jun 13 2016
Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference Jun 01 2016
Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference Jun 01 2016
Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named... Jun 01 2016
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 01 2016
Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named... Jun 01 2016
Sangamo BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : May 23,... May 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)